Therapeutic Role of Vitamin D in Multiple Sclerosis: An Essentially Contested Concept

Mahejabeen Fatima 1, Aselah Lamis 2, Shiza W. Siddiqui 2, Tejaswini Ashok 3, Nasar Patni 4, Olatunji E. Fadiola 5

1. Internal Medicine, Deccan College of Medical Sciences, Hyderabad, IND 2. Research, Dubai Medical College, Dubai, ARE 3. Internal Medicine, JSS Medical College, Mysore, IND 4. Internal Medicine, Deccan College Of Medical Sciences, Hyderabad, IND 5. Internal Medicine, Windsor University School of Medicine, Cayon, KNA

Corresponding author: Mahejabeen Fatima, mahejabeenfatima2@gmail.com

Abstract

Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the nervous system with incredibly intricate etiopathogenesis involving numerous genetic, epigenetic, and environmental risk factors. Major environmental risk factors include ultraviolet (UV) radiation, vitamin D, Epstein-Barr virus (EBV) infection, smoking, and high body mass index (BMI). Vitamin D, in particular, can be viewed as one piece of this puzzle. It is produced in the skin following exposure to sunlight and actively synthesized in the body. Throughout the lifetime, vitamin D is distributed throughout the body based on the exposure to sunlight and food intake. The body can generate approximately 10,000 times more vitamin D in response to sunlight than that from dietary intake. In the liver and kidneys, it is converted to its active form. Vitamin D's role in immune system regulation is considering a multi-functional and multifaceted hormone. It is effective in the regulation of the immune system by influencing the proliferation, differentiation, and function of immune cells. Its potential role in autoimmune disorders all calls for a closer study of its role in MS. The patients from places with less sunlight, low vitamin D levels correlated with an increased risk of MS, and vitamin D’s genetic, lifestyle, and environmental factors playing a role in the causation of the disease. Worldwide, 2.8 million people live with MS, and the disease is four times more common in females than males. It predominantly affects young adults and results in significant disability and decreased quality of life. The disease predominantly affects young adults and results in significant disability and decreased quality of life. The most common form of the disease is the relapsing-remitting type (Relapsing-Remitting Multiple Sclerosis-RRMS); however, some people may have a progressive course from the onset (Primary Progressive Multiple Sclerosis-PPMS) or secondary to the initial relapsing course of the disease (Secondary Multiple Sclerosis-SPMS).

Introduction And Background

In May 1868, Jean-Martin Charcot, a French Neurologist, first assimilated complex clinical and pathological findings to establish a novel neurological disease - sclérose en plaques later referred to in English as Multiple Sclerosis (MS) [1]. Henceforth, it has been elaborated as an immune-mediated inflammatory demyelinating disease affecting the brain, spinal cord, and optic nerves. Worldwide, 2.8 million people live with MS, and the disease is four times more common in females than males [2]. It predominantly affects young adults and results in significant disability and decreased quality of life [2]. The most common form of the disease is the relapsing-remitting type (Relapsing-Remitting Multiple Sclerosis-RRMS); however, some people may have a progressive course from the onset (Primary Progressive Multiple Sclerosis-PPMS) or secondary to the initial relapsing course of the disease (Secondary Multiple Sclerosis-SPMS).

Initial pathology involves inflammatory cell infiltration, demyelination, and axonal damage. Cumulative gliosis following repeated inflammation culminates in chronic neurodegeneration [3]. The first episode of inflammatory demyelination that may become clinical MS if further activity occurs later is identified as Clinically Isolated Syndrome (CIS) [4]. Jean-Martin Charcot’s neurological triad, which includes intention tremor, nystagmus, and scanning speech, was one of the first clinical features of MS to be described. Other critical clinical features include visual dysfunction, diplopia, ataxia, sensory abnormality, spasticity, and bladder dysfunction [5]. This vast landscape of neurological manifestations results from variability in the site and extent of the lesion in the nervous system [1]. The aetiology of MS is a multifactorial process with genetic, lifestyle, and environmental factors playing a role in the causation of the disease [5]. Of the environmental factors, vitamin D, in particular, has piqued interest in recent years. The higher frequency of MS in places with less sunlight, low vitamin D levels linked to an increased risk of MS, and vitamin D’s potential role in preventing autoimmune disorders all call for a closer study of its role in MS [6-8]. The purpose of this article is to review the protective abilities of vitamin D against autoimmunity and its implications in preventing and delaying the course of MS.

Review

Vitamin D and MS - immunopathological stance

Immunologic Background of MS

MS is an immune-mediated chronic inflammatory disease of the central nervous system (CNS). Attempts to
understand the basis of inflammation over the years have presented us with two hypotheses. According to the “inside out” (CNS-intrinsic) hypotheses proposed by Stys et al. primary neuronal degeneration results in the loss of myelin and oligodendrocytes, as well as the release of CNS antigens into the periphery, resulting in an autoimmune inflammatory reaction [9]. The premise of the “outside-in” (CNS-extrinsic) hypothesis explains that the inflammatory trigger first activates immune cells at the periphery, after which they migrate to the CNS and cause demyelination. Both scenarios will result in a negative feedback loop: tissue damage causes antigens to be released to the periphery, which primes new immune responses in lymphoid tissue, followed by lymphocyte invasion into the CNS [10]. The pathogenesis involves dysregulated immune responses and includes cells of both innate and adaptive immune responses [11]. The role of Epstein-Barr virus (EBV) infection in the etiology of MS is consistent with the CNS extrinsic hypothesis. Immunological evidence for this theory includes an increased risk of MS following EBV infection, molecular mimicry between EBV antigens and CNS antigens, and, high levels of anti-EBV antibodies in MS patients [12,13].

**Vitamin D and Immune Function**

The primary site of production of the active form of vitamin D, calcitriol, is in the proximal renal tubular cells. However, the CYP27B1 gene that codes for 1α hydroxylase enzyme which catalyzes the production of calcitriol (1,25(OH)2D) from 25(OH)D (major circulating form of vitamin D) is also expressed in cells outside of renal tissue where calcitriol is known to exert both autocrine and paracrine effects. Calcitriol and nuclear vitamin D Receptor (nVDR) complex bind to Vitamin D Responsive Elements (VDREs) in the promoter sequences of DNA in monocytes, macrophages, and activated lymphocytes inducing differentiation, activation, and proliferation of immune and inflammatory cells [14]. This complex, after binding with transcription factors also regulates inflammatory mediators like tumor necrosis factor-α (TNF-α) and interferon-α (IFN-α) by inhibiting nuclear factor kappa B (NF-κB) [15]. Calcitriol inhibits dendritic cell maturation by suppressing the expression of major histocompatibility complex (MHC) class II, cluster of differentiation (CD)40, CD80, and CD86. It decreases the production of pro-inflammatory cytokines like interleukin (IL)-12 and increases the synthesis of anti-inflammatory cytokines like IL-10 in dendritic cells. Calcitriol inhibits the production of IL-2, IL-17, and IFNs in T cells, as well as the cytotoxic activity and proliferation of CD4+ and CD8+ T cells. It promotes the production and activation of T regulatory cells and inhibits the production of B cell proliferation, differentiation, and immunoglobulin production [16]. The mechanisms through which vitamin D exerts these effects in immune cells are represented in Figure 1.

**FIGURE 1:** Figure showing intracellular mechanisms and immunomodulatory effects of vitamin D in immune cells.

nVDR - Nuclear Vitamin D Receptor, TF - Transcription Factors, RxR - Retinoid X Receptor, NF-κB - Nuclear Factor Kappa B, VDRE - Vitamin D Responsive Elements, DNA - Deoxyribose Nucleic Acid

Image credits- Mahejabeen Fatima

**Vitamin D as a therapeutic aid in MS**
Role of Vitamin D in People at Risk of MS

Pathogenesis of MS involves a complex interplay amongst its genetic and environmental risk factors. However, environmental factors have the most significant impact and genetics only account for a small proportion of variations in the frequency of the disease. MS prevalence rises with increasing latitude among people of similar white ancestry all around the world [17]. Kurtzke, through his study of the epidemiology of MS, demonstrated that the risk for MS decreases two times with migration from high-risk to low-risk areas [18]. Latitude is known to be associated with numerous physical, chemical, biological, and social factors but, it is most tightly correlated with the duration and intensity of sunlight [19]. The findings of Kurtzke supplemented the results of early ecological studies which established an inverse relationship between sunlight exposure and the risk of MS. A multiple regression analysis done on a sample of 454 veterans with a diagnosis of MS born in 29 counties of the US in 1920 indicated that the risk of MS is inversely correlated with daily annual hours of sunshine ($r = -0.75$) and average December daily solar radiation at a place of birth ($r = -0.80$) [20]. This effect of sunlight was thought to be largely due to the resultant increase in vitamin D levels in the body. But the direct relation of sunlight with vitamin D is eliminated in the context of race/ethnicity. Higher levels of serum 25(OH) are associated with decreased MS risk in whites but no such association was found in Blacks and Hispanics [21]. Increasing knowledge about the properties of ultraviolet (UV) radiation and its immunosuppressive effects has delineated sunlight among MS risk factors [22]. Lucas et al. performed a multicenter incident case-control study using a sample population of 611 people with a first demyelinating event (FDEs) between the age of 18 to 59 years residing in Australia (from latitudes 27°S to 43°S), from November 1, 2003, to December 31, 2006. The findings of this study revealed that higher levels of sun exposure (adjusted odds ratio [AOR] = 0.70, 95% confidence interval [CI], 0.53-0.94) for each UV dose increment of 1,000 kl/m$^2$ (range 508-6,397 kl/m$^2$) and higher vitamin D levels (AOR = 0.95, 95% CI, 0.86-1.00) per 10 nmol/L increase in 25(OH)D were independently associated with reduced risk of FDEs [23]. However, the impact of sunlight exposure through vitamin D cannot be entirely excluded. Vitamin D accounts for the 30% effect of sunlight on the risk of MS. Hedström et al. studied two population-based case-control studies and found that the effect of sunlight occurs through vitamin D and non-vitamin D pathways [24].

Sunlight is the most common source of vitamin D for most people. In areas of high MS prevalence, most of the sunlight is absorbed by the atmosphere and even sun exposure for a long time does not produce enough vitamin D. The relationship of latitude with the frequency of MS is inversely in areas predominated with cultures that consume vitamin D enriched diet. Kampman and Brustad observed that in Norway the average vitamin D consumption through food and supplements is equal to the current daily vitamin D intake recommendation for healthy people of 500 IU, which possibly explains why there is no evidence of latitude gradient in MS risk and implies a putative role of higher levels of vitamin D in reducing MS risk [25]. Outside of a normal diet, vitamin D intake through supplements is also associated with decreased MS risk. A large prospective cohort study performed on women taking multivitamins (vitamin D > 400 IU/day) showed a 40% reduction in MS risk. However, the protective role of other vitamins included in multivitamins cannot be excluded [26]. Munger et al. performed a prospective nested case-control study on 257 US military personnel with the diagnosis of MS whose serum samples were stored in the Department of Defense Serum Repository. Estimation of vitamin D status of samples collected before the initial symptoms of MS showed a decreased risk of MS with increasing levels of 25(OH)D (OR for a 50-nmol/L increase in 25(OH)D 0.59; 95% CI, 0.36-0.97). They also observed that this association was stronger for vitamin D levels measured before the age of 20 years [27]. The interactions of vitamin D with other environmental factors are more complex than previously known. A higher body mass index (BMI) is an established risk factor for MS. A recent Mendelian randomization (MR) analysis has provided evidence for this association. The relative contributions of BMI and low vitamin D to MS risk were explored. According to their findings, 5.2% of the increased risk of MS due to obesity is brought about by reduced vitamin D levels and vitamin D supplementation will marginally decrease the effect of obesity on MS [28].

VDREs are abundant in the promoter region of more than 80% of MS-susceptibility genes which when activated by vitamin D alters the expression of such genes [29]. Vitamin D interacts directly with HLA-DRB1*1501 which is the dominant haplotype of the HLA-DRB1 locus found in Northern Europe [30]. It is possible that variations in vitamin D-related genes play a role in disease risk by altering serum levels of 25(OH)D. CYP2R1 gene codes for the 25-Hydroxylase enzyme that converts dietary vitamin D to 25(OH)D in the liver. A low-frequency genetic variation in this gene was identified through genome-wide association studies (GWAS) meta-analysis in the European population. This genetic variant is found to be associated with a two times increase in vitamin D insufficiency and a 40% increase in the risk of MS. Researchers tried to test this interaction between CYP2R1 and dietary vitamin D intake. They did not find any clear interaction in their assessment due to various limitations and proposed need for further study [31]. Similarly, various other vitamin D related genes involved in vitamin D synthesis, catabolism, and regulation of vitamin D metabolism can be responsible for increased MS risk by influencing serum vitamin D levels [30]. Various VDR single nuclear polymorphisms (SNPs) have been studied for their association with MS risk. These studies have shown some positive results but overall, the results are not univocal and remain inconclusive [32,33].

Observational studies have largely been the source of data establishing a link between vitamin D and MS risk. However, there are two notable drawbacks to these studies. The first is confounding, which may be eliminated by matching, and the second is reverse causation. These limitations are successfully overcome by
MR analysis, which allows for the confirmation of a causal role of an exposure on an outcome using genetic variants as instrument variables. A large-scale MR analysis was performed using 25(OH)D-associated single nucleotide polymorphisms (SNPs) as instrument variables and 190 GWAS covering a broad range of diseases and human traits in order to establish a causal role of 25(OH)D. Their results indicate that a genetically predicted increase in 25(OH)D levels markedly reduced the risk of MS (OR = 0.824; 95% CI, 0.689-0.986) [34].

Another study performed by Wang yielded similar results. They used 20 25(OH)D instrument variables and the largest GWAS for 25(OH)D and MS to evaluate the effect of 25(OH)D levels on MS. They found an inverse link between serum 25(OH)D levels and MS risk using MR-egger (Beta = -0.940, p = 0.001; OR = 0.391), weighted median (Beta = -0.835, p = 0.000; OR = 0.435), inverse-variance weighted (IVW) (Beta = -0.781, p = 0.000; OR = 0.458), simple mode (Beta = -1.484, p = 0.016; OR = 0.227), and weighted mode (Beta = -0.913, p = 0.000; OR = 0.401) (Table 1) [35]. The results of these recent studies have only reinforced the findings of earlier MR analyses [36-38].

### REFERENCES

| DESIGN | SAMPLE SIZE | POPULATION | OBJECTIVES | CONCLUSIONS |
|--------|-------------|------------|------------|-------------|
| Langer-Gould et al., (2018) | case-control | Blacks (116 cases/131 controls); Hispanics (183/197); whites (247/267) members of Kaiser Permanente, Southern California | To examine the consistency of beneficial effects of 25OHD and/or sun exposure for MS risk across multiple racial/ethnic groups | Higher serum 25OHD levels were associated with a decreased risk of MS in whites but not in other racial groups. |
| Lucas et al., (2011) | case-control study | 216 cases and 315 controls people between the age of 18 to 59 years with an FDE living in Australia | measures of skin phenotype and acninic damage, and vitamin D status | Sun exposure and vitamin D status independently affect the risk of CNS demyelination. |
| Hedstrom et al., (2019) | case-control study | 7069 cases and 6632 matched controls GEMS study and EIMS study | To determine whether the influence of low sun exposure on MS risk is mediated by low vitamin D levels | Low sun exposure acts both directly on MS risk as well as indirectly, by leading to low vitamin D levels |
| Munger et al., (2004) | Prospective cohort study | NHS: 92,253 NHS II: 95,310 | To assess the protective effect of vitamin D on the risk of MS. | Intake of vitamin D supplements was associated with reduced MS risk. No such association was found with dietary vitamin D |
| Munger et al., (2006) | Prospective nested case-control study | Whites (148 cases, 296 controls) Blacks and Hispanics (109 cases, 218 controls) More than 7 million US military personnel | To examine whether 25(OH)D levels are associated with the risk of MS | High circulating levels of vitamin D are associated with a lower risk of multiple sclerosis. |
| Harroud et al., (2021) | Mendelian randomization study | 14,802 cases and 26,703 controls | The relative role of serum vitamin D levels and varying levels of adiponectin and leptin in the association between obesity and MS. | A minority of the increased risk of MS conferred by obesity is mediated by lowered vitamin D levels, while leptin and adiponectin had no effect |
| Caneila Díez et al., (2021) | Retrospective case-control study | 209 cases and 836 controls Patients with RRMS and healthy controls of Caucasian origin from Southern Spain. | To evaluate the association between polymorphisms in the VDR gene and the risk of MS | Only the VDR FokI (rs2228570) polymorphism was associated with developing MS. |
| Jiang et al., (2021) | Mendelian randomization study | Sample size ranged from 9,954 to 1,030,836 (median 112,561; mean 148,179) 190 GWAS from IEU OpenGWAS Project and NHGRI-EBI GWAS catalogue | To examine a causal role of vitamin D in various phenotypic traits and diseases | Genetically predicted 25(OH)D levels are inversely linked with the risk of MS |
To examine a causal role of vitamin D in MS risk

A causal link between genetically predicted serum 25(OH)D levels and MS risk

TABLE 1: Summary of included studies showing the correlation between Vitamin D and MS risk

| Study                  | Methods                                                                 |
|------------------------|-------------------------------------------------------------------------|
| Wang R (2022)          | Mendelian randomization study, 14,498 cases and 24,091 controls         |
| GWAS of European ancestry | 14,498 cases and 24,091 controls                                      |

| Study                  | Results                                                                 |
|------------------------|-------------------------------------------------------------------------|
| Role of Vitamin D in RRMS | RRMS is the most common form of the disease. It involves a more active course of inflammation with disruption of the blood-brain barrier by activated microglia and infiltration of immune cells. The activity of these immune perpetrators in the neuronal tissue results in demyelinated plaques. This type of acute inflammation has a tendency to recur in the course of the disease [39]. A population-based prospective cohort study performed on 145 people with RRMS residing in Southern Tasmania and Australia from 2002 to 2005 showed that higher 25(OH)D levels were associated with decreased risk of relapse. Each 10 nmol/L increase in 25(OH)D resulted in up to a 12% decrease in relapse risk [40]. These clinical findings also correlate with radiological signs of MS disease activity. A prospective cohort study conducted among 1482 participants with MS in the BEYOND study treated with interferon beta-1b showed that an increase in blood 25(OH)D levels of 50.0 nmol/L were linked to a 31% lower rate of new lesions on MRI (relative rate (RR), 0.69; 95% CI, 0.55-0.86; P =.001). Patients with 25(OH)D levels more than 100.0 nmol/L had the lowest rate of new lesions on MRI (RR, 0.53; 95% CI, 0.37-0.78; P =.002), however, no significant association with relapse rates was observed [41]. In a large multicenter study that followed 1047 clinically isolated syndrome (CIS) cases from 17 different countries for a median of 4.31 years, clinical and biochemical variables were examined to establish their value in predicting CIS advancing to clinically definite multiple sclerosis (CDMS). In univariable analysis, it was observed that the risk of conversion was significantly reduced in patients with high 25(OH)D levels. The same results were not replicated in multivariable analysis where the risk of conversion was decreased but the statistical significance was also diminished simultaneously [42]. Although there is mounting evidence in favour of vitamin D reducing MS risk obtained through observational studies, the same has not been proved conclusive in clinical trials. Mc Laughlin et al. performed a meta-analysis on 12 clinical trials assessing vitamin D in patients with RRMS. Randomized control trials (RCTs) that reported relapse rates, change in Expanded Disability Status Scale (EDSS) and appearance of new radiological signs were selected exclusively. The results of this meta-analysis showed that vitamin D supplementation might be beneficial in preventing relapse rates and new radiological signs. For changes in EDSS, this relationship was found to be relatively strong. However, these changes were not statistically significant for any outcome measure (Table 2) [43]. If the reported correlations in the observational studies could be directly scaled up, this would imply that vitamin D has a massive treatment effect, almost completely eliminating disease activity. The interpretation of data from randomised controlled trials (RCTs) has not proved the same [44]. Possible explanations for this disparity are confounding and reverse causality in observational studies that may have overestimated the influence of vitamin D. RCTs are powered by observational studies and therefore the power calculated for RCTs on vitamin D may not be sufficient enough to detect less prominent effects of vitamin D [44]. |
| REFERENCES                  | DESIGN                          | SAMPLE SIZE | POPULATION                      | OBJECTIVES                                                                 | CONCLUSION                                                                 |
|----------------------------|---------------------------------|-------------|---------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Simpson Jr et al., (2010)  | Prospective cohort study        | 145         | Residents of Southern Tasmania and Australia from 2002 to 2005 with RRMS     | To observe relapse rates in patients of RRMS with higher levels of 25(OH)D | 12% decrease in relapse risk for each 10nmol/L increase in serum 25(OH)D was observed |
| Fitzgerald et al., (2015)  | Prospective cohort study        | 1796        | Patients with RRMS and on IFN-β therapy from 26 countries                  | To assess the association between 25(OH)D and disease activity and progression | A 50.0-nmol/L increase in serum 25(OH)D levels was associated with a 31% lower rate of new lesions |
| Kuhle et al., (2015)       | Multicenter study               | 1047        | Patients with CIS from 17 different countries                              | Predictive value of 25(OH)D in CIS to CDMS conversion                      | Significant predictive value in univariate analysis. Diminished significance in multivariable analysis |
| Mc Laughlin et al., (2018) | Meta-Analysis                   | 950         | Participants of 12 clinical trials                                        | To determine the therapeutic role of vitamin D in MS                       | Statistically insignificant differences in outcome measures                  |

TABLE 2: Summary of studies included assessing the relation between serum vitamin D levels and disease activity

RRMS - Relapsing-Remitting Multiple Sclerosis, CIS - Clinically Isolated Syndrome, CDMS - Clinically Definite Multiple Sclerosis

Simpson Jr et al., [40]; Fitzgerald et al., [41]; Kuhle J et al., [42]; Mc Laughlin et al., [43]

**Role of Vitamin D in Progressive MS**

Patients with progressive MS develop diffuse inflammation involving white matter and the cortex along with chronically demyelinated axons. Effective repair of demyelinated axons following acute inflammation will reduce the burden of disability in these patients [45]. The University of Cambridge reported that vitamin D activates the nVDR, which when paired with the retinoid X receptor (RXR-) leads to downstream signalling and increased differentiation of oligodendrocyte (OLG) progenitor cells into mature OLGs, which are important for myelin synthesis around neurons and are commonly damaged cells in MS. The study also discovered vitamin D receptor expression in oligodendrocyte lineage cells in MS and its activation leading to increased OLG differentiation [46,47]. An experimental study performed on rats has provided support for this hypothesis. Twenty-four male Wistar rats with surgical lesions to the corpus callosum were divided into three groups. Rats from two out of three groups were given lyssolecithin to induce toxic demyelination and rats from one out of three groups were supplemented with vitamin D following lyssolecithin administration. It was observed that vitamin D administration resulted in a proliferation of neuronal stem cells which later differentiated into OLG lineage cells [48].

Ascherio et al. followed up participants of the BENEFIT study with CIS for 5 years clinically and by MRI. According to their observations higher 25(OH)D levels were associated with a slower rate of progression, 25% lower yearly increase in T2 lesion volume (P < .001), and 0.41% lower yearly loss in brain volume (P = .07) from months 12 to 60. 25(OH)D levels greater than or equal to 50 nmol/L (20 ng/mL) predicted lower disability (Expanded Disability Status Scale score, -0.17; P = .004) over the next four years. Lower vitamin D levels in the initial disease course in patients with MS being treated with interferon beta 1-b are associated with long-term MS activity and disease progression (Table 3) [49]. An 11-year follow-up study of the BENEFIT trial was performed by Cortese et al. to examine the effects of vitamin D, smoking, and EBV antibody titers on the cognitive status of patients with MS. According to their results patients with lower vitamin D levels during the course of disease activity are inclined towards worse long-term cognitive function [50]. A similar long-term study was performed by Wesnes et al. where they explored the influence of vitamin D levels, tobacco use, and BMI on disability progression in patients with MS. These parameters were repeatedly measured in 88 patients with RRMS who completed a randomized controlled study on ω-3 fatty acids between 2004 and 2008. EDSS is a tool used to assess clinical disability in MS patients. At follow-up after 10 years in 2017, clinical disability was measured using EDSS among 80 participants. Higher serum 25(OH)D levels were associated with lower 10-year EDSS progression after adjusting for potential confounders [51]. Moreover, self-reported vitamin D supplement use was linked to higher physical and mental quality of life (QoL) cross-sectionally, but only with increased physical QoL prospectively. A study in which data from the HOLISM international cohort was reviewed at 2.5 years indicated higher QoL scores in patients taking vitamin D at an average daily dose of over 50,000IU/d [52].
Ascherio et al., (2004) | 468 | Patients with CIS from 18 European countries, Israel and Canada, participants of the BENEFIT trial | To evaluate serum 25(OH)D levels as a prognostic marker for MS outcomes in patients with CIS | Higher serum 25(OH)D levels were associated with reduced disease activity and rates of progression

Cortese et al., (2020) | 278 | Patients with CIS from 18 European countries, Israel and Canada, participants of the BENEFIT trial | To assess the effect of serum vitamin D levels, smoking and anti EBV antibody concentrations on long term cognitive status in MS patients | Reduced vitamin D levels and smoking during the course of disease results in worse outcomes

Wesnes et al., (2021) | 88 | Patients with RRMS aged between 18 and 55 years in Norway | To determine the association of vitamin D, tobacco use and BMI with disability progression in MS | Only lower vitamin D levels were associated with worse long term disability progression in MS

Simpson-Yap et al., (2021) | | Participants of the HOLISM international cohort | To examine the effect of sun exposure and vitamin D on quality of life | Vitamin D supplement use was linked to higher physical and mental quality of life cross-sectionally, but only with increased physical QoL prospectively.

**TABLE 3: Summary of included studies assessing the effect of vitamin D on long term outcomes of MS**

| REFERENCES | SAMPLE SIZE | POPULATION | OBJECTIVE | CONCLUSION |
|------------|-------------|------------|-----------|------------|
| Ascherio et al., (2004) | 468 | Patients with CIS from 18 European countries, Israel and Canada, participants of the BENEFIT trial | To evaluate serum 25(OH)D levels as a prognostic marker for MS outcomes in patients with CIS | Higher serum 25(OH)D levels were associated with reduced disease activity and rates of progression |
| Cortese et al., (2020) | 278 | Patients with CIS from 18 European countries, Israel and Canada, participants of the BENEFIT trial | To assess the effect of serum vitamin D levels, smoking and anti EBV antibody concentrations on long term cognitive status in MS patients | Reduced vitamin D levels and smoking during the course of disease results in worse outcomes |
| Wesnes et al., (2021) | 88 | Patients with RRMS aged between 18 and 55 years in Norway | To determine the association of vitamin D, tobacco use and BMI with disability progression in MS | Only lower vitamin D levels were associated with worse long term disability progression in MS |
| Simpson-Yap et al., (2021) | | Participants of the HOLISM international cohort | To examine the effect of sun exposure and vitamin D on quality of life | Vitamin D supplement use was linked to higher physical and mental quality of life cross-sectionally, but only with increased physical QoL prospectively. |

**Prognostic value of vitamin D in MS**

It may be implied that vitamin D while being involved in causation also influences the course of the disease and long-term disability outcomes [26,54]. While causality was established through Mendelian randomization studies, observational studies showed that lower levels of 25(OH)D were linked to increased risk of disease, higher rates of relapses, and worse long-term outcomes. However, clinical trials did not prove this influence to be true. Clinical trials performed thus far may have shown some benefit of 25(OH)D on disease activity but they did not prove any significant effect on the primary outcome of the trials. Particularly, the studies performed to assess the effect of vitamin D on disease activity did not provide such evidence.

**Limitations**

Multiple sclerosis is a multifactorial disease and this article focuses only on one entity of its etiopathogenesis. As mentioned in this article, vitamin D interacts with other environmental and genetic factors of the disease. Therefore, its effect on the disease risk, activity, and progression cannot be entirely delineated. A small proportion of studies showing contradictory results pertaining to the current topic have not been included in this review.

**Conclusions**

Vitamin D appears to have numerous associations with various etiological factors of MS. Most of the MS susceptibility genes have been known to closely interact with vitamin D. It is directly associated with disease risk and activity due to its homeostatic role in the immune system. Mendelian randomization studies have also proved a causal relationship between low vitamin D levels and the risk of MS. Mutations in genes that code for the enzymes involved in the metabolic pathway of vitamin D synthesis as well as degradation and VDR SNPs are also implicated in the aetiology of MS. Various epidemiological and observational studies have proposed that higher levels of vitamin D are linked with decreased risk of relapses and slower progression of the disease. Clinical trials due to some limitations have largely been inconclusive about the effect of vitamin D on disease activity. Therefore, the use of vitamin D, as opposed to current highly efficacious disease-modifying treatments, remains unproven. Larger placebo-controlled randomized control trials are needed in order to endorse vitamin D supplementation as focal therapy in the treatment of MS.
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Zalc B: One hundred and fifty years ago Charcot reported multiple sclerosis as a new neurological disease. Brain. 2018, 141:5482-8. 10.1093/brain/awy287
2. Walton C, King R, Rechtman L, et al.: Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020, 26:1816-21. 10.1177/1352458520970841
3. Compton A, Coles A: Multiple sclerosis. Lancet. 2008, 25:1502-17. 10.1016/S0140-6736(08)61620-7
4. Lublin FD, Reingold SC, Cohen JA, et al.: Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014, 85:278-86. 10.1212/WNL.0000000000000560
5. Olsson T, Barcellos LF, Alfredsson L: Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017, 13:25-36. 10.1038/nrneurol.2016.187
6. Ascherio A, Munger KL: Epidemiology of multiple sclerosis: from risk factors to prevention—an update. Semin Neurol. 2016, 36:103-14. 10.1055/s-0036-1579695
7. Pierrot-Deseligny C, Souberbielle JC: Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis. Ther Adv Neurol Disord. 2015, 8:681-116. 10.1177/1756285614527513
8. Pariot B, Treiber G, Pieber TR, Amrein K: Vitamin D and immune function. Nutrients. 2015, 5:2502-21. 10.3390/nu5072502
9. Stys PK, Zamponi GW, van Minnen J, Geurts J: Will the real multiple sclerosis please stand up?. Nat Rev Neurol. 2012, 18:507-14. 10.1038/nrneurol.2012.327
10. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O: Multiple sclerosis. Lancet. 2018, 391:1622-56. 10.1016/S0140-6736(18)30481-1
11. Bar-Or A, Li R: Cellular immunity of relapsing multiple sclerosis: interactions, checks, and balances. Lancet Neurol. 2021, 20:470-83. 10.1016/S1474-4422(21)00063-6
12. Bjornevik K, Cortese M, Healy BC, et al.: Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022, 373:296-301. 10.1126/science.abc2223
13. Lanz TV, Brewer RC, Ho PP, et al.: Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GliACAM. Nature. 2022, 653:321-7. 10.1038/s41586-022-04432-7
14. DeLuca HF: The vitamin D story: a collaborative effort of basic science and clinical medicine. FASEB J, 1988, 2:224-56.
15. Chen Y, Zhang J, Ge X, Du J, Deb DK, Li YC: Vitamin D receptor inhibits nuclear factor kB activation by interacting with IκB kinase β protein. J Biol Chem. 2015, 288:19450-8. 10.1074/jbc.M115.667679
16. Sinzelt MB, Rametta M, Reder AT: Vitamin D and multiple sclerosis: a comprehensive review. Neurol Ther. 2018, 7:59-85. 10.1007/s40120-017-0086-4
17. Ascherio A, Munger KL: Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2008, 61:288-99. 10.1002/ana.21117
18. Kurtzke JF: Geography in multiple sclerosis. J Neurol. 1977, 215:1-26. 10.1007/BF00312546
19. Ascherio A, Munger KL: Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol. 2007, 61:504-13. 10.1002/ana.21141
20. AC ED, BA CA, WR FM: Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatr Scand Suppl. 1960, 35:132-47. 10.1111/j.1600-4471.1960.tb08674.x
21. Langer-Gould A, Lucas R, Xiang AH, et al.: MS sunshine study: sun exposure but not vitamin D is associated with multiple sclerosis risk in Blacks and Hispanics. Nutrients. 2018, 10:10039. 10.1007/s40120-018-09677-3
22. Ostkamp P, Salmen A, Piggnetal B, et al.: Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. Proc Natl Acad Sci U S A. 2021, 118:110.1073/pnas.2018477118
23. Lucas RM, Ponsonby AL, Dear K, et al.: Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology. 2011, 76:540-8. 10.1212/WNL.0b013e318218204a95d
24. Hedström AK, Olsson T, Kockum I, Hillert J, Alfredsson L: Low sun exposure increases multiple sclerosis risk both directly and indirectly. J Neurol. 2020, 267:1045-52. 10.1007/s00415-019-09677-5
25. Kampman MT, Brustad M: Vitamin D: a candidate for the environmental effect in multiple sclerosis - Observations from Norway. Neuropediatrics. 2008, 39:40-6. 10.1159/000122230
26. Munger KL, Zhang SM, O'Reilly E, Hernán MA, Olek MJ, Willett WC, Ascherio A: Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004, 62:60-5. 10.1212/01.wnl.00000101725.79681.38
27. Munger KL, Levin LJ, Hollis BW, Howard NS, Ascherio A: Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006, 296:2852-8. 10.1001/jama.296.25.2852
28. Harroud A, Manousakis D, Butler-Laporte G, Mitchell RE, Davey Smith G, Richards JB, Baranzini SE: The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: a Mendelian randomization mediation analysis. Mult Scler. 2021, 27:1994-2000. 10.1177/1352458521995484
29. Ramagopalan SV, Heger A, Berlanga AJ, et al.: A ChiP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 2010, 20:1532-60. 10.1101/gr.107920.110
30. Ramagopalan SV, Maugeri NJ, Handunnetthi L, et al.: Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet. 2009, 5:e1000569. 10.1371/journal.pgen.1000569
51. Manoussiad D, Dudding T, Haworth S, et al.: Low-frequency synonymous coding variation in CYP2R1 has large effects on vitamin D levels and risk of multiple sclerosis. Am J Hum Genet. 2017, 101:227-38. 10.1016/j.ajhg.2017.06.014

52. Scazzone C, Agnello L, Bivona G, Lo Sasso B, Ciaccio M: Vitamin D and genetic susceptibility to multiple sclerosis. Biochem Genet. 2021, 59:1-30. 10.1007/s10528-020-00100-1

53. Caneva Diez B, Pérez-Ramírez C, Maldonado-Montoro MD, et al.: Association between polymorphisms in the vitamin D receptor and susceptibility to multiple sclerosis. Pharmacogenet Genomics. 2021, 31:40-7. 10.1097/FPC.0000000000000420

54. Jiang X, Ge T, Chen CY: The causal role of circulating vitamin D concentrations in human complex traits and diseases: a large-scale Mendelian randomization study. Sci Rep. 2021, 11:184. 10.1038/s41598-020-80655-w

55. Wang B: Mendelian randomization study updates the effect of 25-hydroxyvitamin D levels on the risk of multiple sclerosis. J Transl Med. 2022, 20:5. 10.1186/s12976-021-00320-5

56. Mokry LE, Ross S, Ahmad OS, et al.: Vitamin D and risk of multiple sclerosis: a Mendelian randomization study. PLoS Med. 2015, 12:e1001866. 10.1371/journal.pmed.1001866

57. Rhead B, Bäärnhielm M, Gianfrancesco M, et al.: Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk. Neurol Genet. 2016, 2:e97. 10.1212/NXG.0000000000000097

58. Gianfrancesco MA, Stridh P, Rhead B, et al.: Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. Neurology. 2017, 88:1625-9. 10.1212/WNL.000000000005849

59. Lassmann H: Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci. 2013, 333:1-4. 10.1016/j.jns.2013.05.010

60. Simpson S Jr, Taylor B, Blizzard L, et al.: Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010, 68:193-205. 10.1002/ana.22043

61. Fitzgeral KC, Munger KL, Köchert K, et al.: Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. JAMA Neurol. 2015, 72:1458-65. 10.1001/jamaneurol.2015.2742

62. Kuhle J, Disanto G, Dobson R, et al.: Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult Scler. 2015, 21:1013-24. 10.1177/1352458514568827

63. McLaughlin L, Clarke L, Khalilidehkordi E, Butzkueven H, Taylor B, Broadley SA: Vitamin D for the treatment of multiple sclerosis: a meta-analysis. J Neurol. 2018, 265:2895-905. 10.1007/s00415-018-9074-6

64. Smolders J, Torkildsen Ø, Camu W, Holmøy T: An update on vitamin D and disease activity in multiple sclerosis. CNS Drugs. 2019, 33:1187-99. 10.1007/s40263-019-00674-8

65. Branow S, Frischer M, Lassmann H, Koch-Henriksen N, Lucchini CF, Sørensen PS, Laursen H: Demyelination versus remyelination in progressive multiple sclerosis. Brain. 2010, 133:2985-98. 10.1093/brain/awq250

66. de la Fuente AG, Errea O, van Wijngaarden P, et al.: Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation. J Cell Biol. 2015, 211:973-85. 10.1083/jcb.201505119

67. Shirazi HA, Rasoulj M, Ciaccio M, Zhang GX: 1,25-Dihydroxyvitamin D3 enhances neural stem cell proliferation and oligodendrocyte differentiation. Exp Mol Pathol. 2015, 98:240-5. 10.1016/j.yexmp.2015.02.004

68. Gomez-Pinero U, Cuneva JA, Benito-Martín MS, et al.: Vitamin D increases remyelination by promoting oligodendrocyte lineage differentiation. Brain Behav. 2020, 10:e01498. 10.1002/brb3.1498

69. Acherio A, Munger KL, White R, et al.: Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014, 71:506-14. 10.1001/jamaneurol.2013.5993

70. Cortese M, Munger KL, Martínez-Lapiscina EH, et al.: Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT. Neurology. 2020, 94:e1950-60. 10.1212/WNL.0000000000009571

71. Weisner K, Myhr KM, Riise T, et al.: Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis. Mult Scler Relat Disord. 2021, 50:102801. 10.1016/j.msard.2021.102801

72. Simpson-Yap S, Jelinek P, Weiland T, Nag N, Neate S, Jelinek G: Self-reported use of vitamin D supplements is associated with higher physical quality of life scores in multiple sclerosis. Mult Scler Relat Disord. 2021, 49:102760. 10.1016/j.msard.2021.102760